Sudarshan Pharma Industries Ltd strategy deck summary

Strategy deck of 31 Jan 2026, summarised by AI from the filing.

Revenue from operations ₹168.01 cr (Q2 FY26: ₹168.87 cr; Q1 FY26: ₹145.26 cr).

Key takeaways

1. Q3 FY26 revenue Revenue from operations ₹168.01 cr (Q2 FY26: ₹168.87 cr; Q1 FY26: ₹145.26 cr).
2. Margin drivers Company attributes FY25 EBITDA margin growth to higher exports and manufacturing sales and maximizing profit margin on resale of API in local markets.
3. China dependency High dependency on China for raw material of specialty chemicals, intermediates and excipients exposes manufacturers to price volatility and inconsistent supply.

Original filing on BSE

Sudarshan Pharma Industries Ltd earnings call, investor presentation and press release summaries

• Q4 FY25: Results deck (2 May 2025)
• Other events: Strategy deck (18 Aug 2026), Strategy deck (14 Aug 2026), Strategy deck (15 May 2026), Strategy deck (31 Jan 2026), Strategy deck (14 Aug 2025)